Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20676910 | 1.00 | CYP2D6 (0.41) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL20686275 | 0.79 | BRD4 (0.36) | CYP2C19KMT2A | |
| SCHEMBL28563089 | 0.79 | BRD4 (0.36) | CYP2C19KMT2A | |
| SCHEMBL26699102 | 0.75 | CYP2D6 (0.37) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL19401497 | 0.69 | DDB1 (0.35) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL20677137 | 0.69 | DDB1 (0.35) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL9037558 | 0.69 | — | — | |
| SCHEMBL24993681 | 0.63 | GLA (0.37) | — | |
| SCHEMBL24993683 | 0.62 | NCF1 (0.31) | — | |
| SCHEMBL12995468 | 0.62 | MAPT (0.50) | LMNAALOX15CYP1A2CYP2C19THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025119195-A1 | COMBINATION OF POLQ INHIBITOR AND ANTI-CANCER THERAPEUTIC AGENT | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2025-06-12 | — | — | WO | disclosed |
| CN-119255992-A | Heterocyclic derivatives, compositions and uses thereof | 北京丹擎医药科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2023226964-A1 | HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| CN-113666922-A | Internal sulfonamide compounds and methods of use thereof | 正大天晴药业集团股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| US-11111240-B2 | Sultam compound and application method thereof | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-09-07 | — | — | US | disclosed |
| US-11111240-B2 | Sultam compound and application method thereof | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-09-07 | — | — | US | disclosed |
| CN-109071471-B | Internal sulfonamide compounds and methods of use thereof | 正大天晴药业集团股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-20210047314-A1 | Sultam Compound And Application Method Thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
| US-20210047314-A1 | Sultam Compound And Application Method Thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
| EP-3434671-B1 | SULTAM COMPOUND AND APPLICATION METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-10-21 | — | — | EP | disclosed |
| EP-3434671-B1 | SULTAM COMPOUND AND APPLICATION METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-10-21 | — | — | EP | disclosed |
| EP-3434671-A1 | SULTAM COMPOUND AND APPLICATION METHOD THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| EP-3434671-A1 | SULTAM COMPOUND AND APPLICATION METHOD THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| CN-109071471-A | Internal sulfonamide compounds and methods of use thereof | 正大天晴药业集团股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2017162157-A1 | SULTAM COMPOUND AND APPLICATION METHOD THEREOF | 正大天晴药业集团股份有限公司 | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111240-B2 | Sultam compound and application method thereof | IDH1, IDH3A, IDH3B | CYP2D6 208/4885LMNA 4290/4885BLM 3048/4885 |
| US-20210047314-A1 | Sultam Compound And Application Method Thereof | IDH1, IDH3A, IDH3B | CYP2D6 208/4885LMNA 4290/4885BLM 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.